ArticleNeuroradiology2026
Early experience with the Surpass Elite flow diverter for unruptured intracranial aneurysms.
Article in Neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe Surpass Elite (Stryker Neurovascular) is the latest generation of the Surpass flow diverter (FD) platform, featuring a higher braid angle consistently exceeding 150°, the BioStealth surface modification, and an expanded size matrix. We report our early single-center experience with the Surpass Elite in the treatment of intracranial aneurysms.
methodsRetrospective analysis of a prospectively maintained database including 21 consecutive patients with 22 intracranial aneurysms treated with the Surpass Elite between March 2025 and January 2026 at a single high-volume neurointerventional center. We recorded and analyzed device deployment characteristics and imaging and clinical follow-up, as well as intraprocedural, early (< 30 days), and delayed (> 30 days) neurological complications.
resultsTwenty-one patients (16 women, mean age 47 years) were treated for 22 aneurysms (3 previously ruptured, all saccular). Twenty-four devices were successfully deployed (mean of 1.1 devices per patient), with a 100% technical success rate. Five procedures (23.8%) were performed via radial access. No intraprocedural, early, or delayed neurological complications were observed. No intracranial hemorrhage or mortality occurred. All patients maintained a modified Rankin Scale score of 0 throughout follow-up. Imaging follow-up, available in 19/22 (86.4%) aneurysms (median 5 months), demonstrated complete occlusion (OKM grade D) in 12/19 (63.2%) and adequate occlusion (OKM grades C-D) < in 16/19 (84.2%).
conclusionWithin the limits of a small single-center cohort and short imaging follow-up, our early experience with the Surpass Elite suggests favorable technical performance, an encouraging safety profile, and early occlusion rates consistent with previously reported flow diverters. Larger multicenter prospective studies with imaging follow-up extended to 12-24 months are warranted to confirm these preliminary findings.
Indexed as
Identifiers
42228146What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.